Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases

Journal for ImmunoTherapy of Cancer

Volumn 4, Issue 1, 2016, Pages

  Kolla, Bhaskar C ^a   Patel, Manish R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Immune related adverse effects; Immunotherapy; Lung cancer; Nivolumab; Pericardial effusion; Pericardial tamponade; Recurrent pleural effusions

Indexed keywords

AFATINIB; AURORA KINASE INHIBITOR; BEVACIZUMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; NIVOLUMAB; OSIMERTINIB; PREDNISONE; SUNITINIB; TEMOZOLOMIDE; TOPOTECAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADENOCARCINOMA; ADULT; ADVERSE DRUG REACTION; ARTICLE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HEART TAMPONADE; HUMAN; IMMUNE RELATED ADVERSE EFFECT; LUNG CANCER; LYMPHADENOPATHY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PLEURA EFFUSION; PRIORITY JOURNAL; PSEUDOPROGRESSION; RECURRENT DISEASE; SKULL IRRADIATION; STEREOTACTIC BODY RADIATION THERAPY; SUPERIOR CAVA VEIN SYNDROME; THORACOCENTESIS; TREATMENT RESPONSE; BIOPSY; COMPLICATION; MOLECULARLY TARGETED THERAPY; NEOPLASM; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOPSY; CARDIAC TAMPONADE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; PERICARDIAL EFFUSION; PLEURAL EFFUSION; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; RECURRENCE;

EID: 84997724774     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0185-2     Document Type: Article

References (11)

1. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv324.
2. Nishino M, Jagannathan JP, Krajewski KM, O'Regan K, Hatabu H, Shapiro G, Ramaiya NH. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol. 2012;198:737-45.
3. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G. A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007;30:1-15.
4. Di Giacomo AM, Danielli R, Guidoboni M, Calabro L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58:1297-306.
5. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-20.
6. Kazandjian DG, Blumenthal GM, Khozin S, Suzman DL, Keegan P, Pazdur R. Characterization of patients treated with a programmed cell death protein 1 inhibitor (anti-PD-1) past RECIST progression from a metastatic non-small cell lung cancer (mNSCLC) trial. J Clin Oncol. 2016;34(suppl; abstr 3000).
7. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541-3.
8. al SJAe. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol. 2015;33:2015.
9. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375-91.
10. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-39.
11. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus docetaxel in advanced Squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-35.